




Searching News Database: abetimus sodium
HSMN NewsFeed - 11 Feb 2008
La Jolla Pharmaceutical Company Reports Progress in International Phase 3 Riquent(R) Study
La Jolla Pharmaceutical Company Reports Progress in International Phase 3 Riquent(R) Study
HSMN NewsFeed - 10 May 2007
La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
HSMN NewsFeed - 20 Mar 2007
La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
HSMN NewsFeed - 8 Mar 2007
La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
HSMN NewsFeed - 6 Nov 2006
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
HSMN NewsFeed - 27 Sep 2006
La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent(R) Study
La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent(R) Study
HSMN NewsFeed - 17 Jul 2006
Michael Tansey, M.D. Joins La Jolla Pharmaceutical Company as Chief Medical Officer
Michael Tansey, M.D. Joins La Jolla Pharmaceutical Company as Chief Medical Officer
Additional items found! 6

Members Archive contains
6 additional stories matching:
abetimus sodium
(Password required)
abetimus sodium
(Password required)